Page | |
EDITORIALS |
5 | Recommendations from The Medical Education Editor
|
8 | Continuous positive airway pressure or high-flow nasal cannula oxygen therapy for acute hypoxemic respiratory failure unrelated to COVID-19: Another brick in the wall?
|
11 | This time the canary is the coal mine
|
14 | Untangling the relationship between childhood risk factors and obstructive sleep apnoea in adulthood
|
16 | Pre-transplant anti-fibrotics for idiopathic pulmonary fibrosis: Are we seeing a new role for the anti-fibrotics?
|
COMMENTARIES |
18 | Adaptation in real time: Wildfire smoke exposure and respiratory health
|
21 | Pathogens of importance in lung disease—Implications of the WHO fungal priority pathogen list
|
INVITED REVIEW SERIES |
Treatable traits - Personalised Medicine for Life in Airway Disease |
24 | Treatable traits models of care
|
ORIGINAL ARTICLES |
Critical Care |
36 |
Continuous positive airway pressure versus high-flow nasal cannula oxygen therapy for acute hypoxemic respiratory failure: A randomized controlled trial
Kazuma Nagata, Toshiki Yokoyama, Ryosuke Tsugitomi, Harunori Nakashima, Hiroshi Kuraishi, Shinichiro Ohshimo, Yoshihiro Mori, Masaaki Sakuraya, Ryogo Kagami, Motoaki Tanigawa, Kazunori Tobino, Tetsuro Kamo, Toru Kadowaki, Yasutaka Koga, Yoshitaka Ogata, Naoki Nishimura, Yasuhiro Kondoh, Satsuki Taniuchi, Ayumi Shintani, Keisuke Tomii, on behalf of the JaNP-Hi Study Investigators
10.1111/resp.14588
In patients with acute hypoxemic respiratory failure, compared with high-flow nasal cannula oxygen therapy, continuous positive airway pressure reduced the risk of meeting the criteria for intubation.
See related editorial |
Interstitial Lung Disease |
46 | Dyspnoea relief as an inherent benefit of high flow nasal cannula therapy: A laboratory randomized trial in healthy humans
Clara Bianquis, Camille Rolland-Debord, Isabelle Rivals, Thomas Similowski, Capucine Morélot-Panzini
10.1111/resp.14580
High-flow nasal cannula therapy relieves acute experimental breathlessness induced by thoracoabdominal elastic loading in healthy subjects, independent of oxygen addition. Modulation of the central integration of respiratory afferences may be involved in the dyspnoea alleviation. |
Respiratory Infections |
56 | Long-term effects of extreme smoke exposure on COVID-19: A cohort study
Tyler J Lane, Matthew Carroll, Brigitte M Borg, Tracy A McCaffrey, Catherine L Smith, Caroline X Gao, David Brown, David Poland, Shantelle Allgood, Jillian Ikin, Michael J Abramson
10.1111/resp.14591
Surveying a cohort established before the pandemic, we investigated long-term COVID-19 vulnerability due to coalmine fire smoke exposure. There was a positive but generally non-significant association between PM2.5 and COVID-19. It would therefore be prudent to treat extreme but discrete coalmine fire smoke as a long-term COVID-19 risk factor.
See related editorial |
Sleep and Ventilation |
63 | Associations of early life and childhood risk factors with obstructive sleep apnoea in middle-age
Chamara V Senaratna, Adrian Lowe, E Haydn Walters, Michael J Abramson, Dinh Bui, Caroline Lodge, Bircan Erbas, John Burgess, Jennifer L Perret, Garun S Hamilton, Shyamali C Dharmage
10.1111/resp.14592
This study provides the first known evidence for individual and profiled early-life and childhood risk factors for OSA in adults. It shows that early exposures to smoking and lower respiratory tract infections could be risks for adult OSA, which may stimulate future research and help flag future risk of OSA.
See related editorial |
Thoracic Surgery |
71 | Effect of antifibrotic agents on postoperative complications after lung transplantation for idiopathic pulmonary fibrosis
Elsa Moncomble, Gaelle Weisenburger, Clément Picard, Tristan Dégot, Martine Reynaud-Gaubert, Ana Nieves, Jean François Mornex, Gaelle Dauriat, Jonathan Messika, Cendrine Godet, Sandrine Hirschi, Jérôme Le Pavec, Raphael Borie, Pierre Mordant, Brice Lortat-Jacob, Hervé Mal, Vincent Bunel
10.1111/resp.14605
This multi-centre nationwide, retrospective study including 58 patients receiving antifibrotic agents before lung transplantation for idiopathic pulmonary fibrosis shows that their use did not increase airway, bleeding or wound post-operative complications and could be associated with reduced rates of primary graft dysfunction and 90-day mortality.
See related editorial |
FORUM AND DEBATE |
Personal Reflection |
80 | Respirology and family medicine
|
Letter from Asia-Pacific and Beyond |
82 | Letter from Argentina
|